News & Updates

At the second interim analysis of part 1 of the phase III RUBY study, updated duration of response (DoR) findings suggest that women with primary advanced or recurrent endometrial cancer who have achieved a response with the combination regimen comprising dostarlimab and carboplatin-paclitaxel (CP) have substantially improved DoR.

Long-term treatment with tirzepatide results in improved renal function in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, regardless of the absence or presence of chronic kidney disease (CKD), according to a post hoc analysis of the SUMMIT trial presented at ACC.25.

Initial results of the phase I RUTIVAC-1 study show the potential of two doses of a tuberculosis (TB) vaccine given after surgery but before standard BCG* treatment to boost immunity and reduce the odds of recurrence in patients with non-muscle-invasive bladder cancer (NMIBC).

In the treatment of mild to moderate erectile dysfunction (ED), low-intensity extracorporeal shockwave therapy combined with tadalafil helps improve outcomes, according to the preliminary results of a study from China.

A stepwise dual antiplatelet therapy (DAPT) de-escalation strategy among patients with acute coronary syndrome (ACS) who could be treated by paclitaxel-coated balloons without stents demonstrates noninferiority to the standard 12-month DAPT for all net adverse clinical events, according to a study.